my personal edition > depression > news
E-Mail this DGNews to a colleague
DGNews
Updated Product Information for Efexor
LONDON, U.K. -- May 31, 2006 -- The Medicines and Healthcare products Regulatory Agency (MHRA) has concluded its review into all the latest safety evidence relating to Efexor (venlafaxine), an antidepressant belonging to a class of medicines known as selective serotonin reuptake inhibitors (SSRIs).
The review particularly looked at the risks associated with overdose.
Updated prescribing advice is designed to minimise the risks of side effects, especially in overdose. The main points are:
The need for specialist supervision in those severely depressed or hospitalised patients who need doses of 300mg daily or more.
· Cardiac contra-indications are more targeted towards high risk groups.
· As previously, patients with uncontrolled hypertension should not take venlafaxine, and blood pressure monitoring is recommended for all patients.
· Updated advice on possible drug interactions.
In addition, a smaller pack size will soon be available to help minimise the risk of overdose.
The MHRA is informing healthcare professionals about the updated prescribing advice. The Patient Information Leaflet (PIL) will also be updated, incorporating all the new advice.
Dr June Raine, MHRA Director said, "We are writing to healthcare professionals to ensure that they are fully informed of the updated information on Efexor to allow them to make informed prescribing decisions. It is very important that patients do not stop their treatment. Patients already taking Efexor should make a routine appointment with their doctor, so that their treatment can be reviewed. For most patients, no changes to their treatment will be needed."
Patients and healthcare professionals are urged to report any suspected adverse reactions to Efexor via the Yellow Card Scheme. They can be completed on the web at www.yellowcard.gov.uk
SOURCE: Medicines and Healthcare Products Regulatory Agency
All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.
| 
